CA2875470C - Tailored liposomes for the treatment of bacterial infections - Google Patents

Tailored liposomes for the treatment of bacterial infections Download PDF

Info

Publication number
CA2875470C
CA2875470C CA2875470A CA2875470A CA2875470C CA 2875470 C CA2875470 C CA 2875470C CA 2875470 A CA2875470 A CA 2875470A CA 2875470 A CA2875470 A CA 2875470A CA 2875470 C CA2875470 C CA 2875470C
Authority
CA
Canada
Prior art keywords
empty liposomes
sphingomyelin
liposomes
cholesterol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2875470A
Other languages
English (en)
French (fr)
Other versions
CA2875470A1 (en
Inventor
Eduard Babiychuk
Annette Draeger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Publication of CA2875470A1 publication Critical patent/CA2875470A1/en
Application granted granted Critical
Publication of CA2875470C publication Critical patent/CA2875470C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CA2875470A 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections Active CA2875470C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12171924.9 2012-06-14
EP12171924 2012-06-14
EP13153039.6 2013-01-29
EP13153039 2013-01-29
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CA2875470A1 CA2875470A1 (en) 2013-12-19
CA2875470C true CA2875470C (en) 2021-01-12

Family

ID=48703423

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2875470A Active CA2875470C (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Country Status (19)

Country Link
US (4) US10744089B2 (https=)
EP (2) EP2861214B1 (https=)
JP (2) JP6382801B2 (https=)
CN (2) CN104602672B (https=)
AU (2) AU2013276565B2 (https=)
BR (1) BR112014031278B1 (https=)
CA (1) CA2875470C (https=)
CY (1) CY1123337T1 (https=)
DK (1) DK2861214T3 (https=)
ES (1) ES2821502T3 (https=)
HR (1) HRP20201761T1 (https=)
HU (1) HUE051761T2 (https=)
LT (1) LT2861214T (https=)
PL (1) PL2861214T3 (https=)
RS (1) RS60951B1 (https=)
RU (1) RU2672106C2 (https=)
SI (1) SI2861214T1 (https=)
SM (1) SMT202000584T1 (https=)
WO (1) WO2013186286A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2861214T3 (pl) * 2012-06-14 2021-02-08 Universität Bern Liposomy przystosowane do leczenia zakażeń bakteryjnych
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CA3009119A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
EP3440187A1 (en) 2016-04-07 2019-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
SI3471732T1 (sl) 2016-06-16 2020-09-30 Combioxin Sa Liposomi za zdravljenje virusnih infekcij
EP3589278B1 (en) 2017-03-02 2026-01-14 Combioxin SA Liposomes for inhibiting biofilm formation
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
SMT202300391T1 (it) 2018-04-17 2024-01-10 Combioxin Sa Trattamento della polmonite
FI3781210T3 (fi) * 2018-04-20 2024-09-12 Combioxin Sa Hypotension hoito sepsiksen tai septisen sokin yhteydessä
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
WO2021150460A1 (en) 2020-01-20 2021-07-29 Arytha Biosciences Llc Devices containing cellular membrane and uses thereof
JP2023536833A (ja) * 2020-07-31 2023-08-30 サインパス ファルマ，インク． サイトカイン放出及びサイトカインストームの抑制
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 纳米解毒剂及其在中和mrsa穿孔毒素的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641247A (en) 1970-12-14 1972-02-08 Stanley Drug Products Inc Methods of treating bacterial infections
AU6428890A (en) * 1989-09-12 1991-04-18 Regents Of The University Of California, The Therapeutic peptides and proteins
NL9000207A (https=) * 1990-01-29 1991-08-16 Duphar Int Res
AU2583892A (en) * 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
CA2467064C (en) * 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
KR100746141B1 (ko) 2002-03-08 2007-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 전시냅스성 단백질 р120
EP1531828A4 (en) 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
JP4874547B2 (ja) * 2002-11-26 2012-02-15 ギリアード サイエンシーズ， インコーポレイテッド 勾配によるリポソームへの薬物充填方法
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
CA2928387A1 (en) 2004-05-03 2005-11-17 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
WO2007018275A1 (ja) 2005-08-11 2007-02-15 National Institute Of Advanced Industrial Science And Technology ローリングモデルに基づく、送達媒体の設計
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
WO2008058156A2 (en) * 2006-11-06 2008-05-15 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
CN101623262B (zh) * 2009-08-24 2011-02-02 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂
JP2013529638A (ja) * 2010-06-19 2013-07-22 ウェスタン ユニバーシティ オブ ヘルス サイエンス Ｐｅｇ化リポソーム封入糖ペプチド抗生物質の新規製剤
US10272040B2 (en) * 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
CN102327220B (zh) 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
PL2861214T3 (pl) 2012-06-14 2021-02-08 Universität Bern Liposomy przystosowane do leczenia zakażeń bakteryjnych
WO2017222912A1 (en) 2016-06-20 2017-12-28 Vivacelle Bio, Inc. Compositions and methods for reducing reperfusion injury
EP3589278B1 (en) 2017-03-02 2026-01-14 Combioxin SA Liposomes for inhibiting biofilm formation
SMT202300391T1 (it) 2018-04-17 2024-01-10 Combioxin Sa Trattamento della polmonite

Also Published As

Publication number Publication date
CY1123337T1 (el) 2021-12-31
JP6656321B2 (ja) 2020-03-04
SMT202000584T1 (it) 2020-11-10
DK2861214T3 (da) 2020-10-12
HRP20201761T1 (hr) 2020-12-25
RU2672106C2 (ru) 2018-11-12
RU2018138012A (ru) 2019-03-21
AU2013276565B2 (en) 2018-12-20
CN104602672B (zh) 2018-12-25
AU2019201776A1 (en) 2019-04-04
US20150157570A1 (en) 2015-06-11
EP2861214B1 (en) 2020-08-05
US10744089B2 (en) 2020-08-18
US20220087934A1 (en) 2022-03-24
CA2875470A1 (en) 2013-12-19
JP2015519383A (ja) 2015-07-09
JP6382801B2 (ja) 2018-08-29
JP2018184470A (ja) 2018-11-22
US20200345639A1 (en) 2020-11-05
CN109549925A (zh) 2019-04-02
SI2861214T1 (sl) 2021-01-29
RS60951B1 (sr) 2020-11-30
CN104602672A (zh) 2015-05-06
BR112014031278B1 (pt) 2020-12-01
CN109549925B (zh) 2022-06-17
LT2861214T (lt) 2020-12-28
WO2013186286A1 (en) 2013-12-19
AU2019201776B2 (en) 2020-11-12
AU2013276565A1 (en) 2014-12-18
US20230031648A1 (en) 2023-02-02
HK1210018A1 (en) 2016-04-15
ES2821502T3 (es) 2021-04-26
EP2861214A1 (en) 2015-04-22
US12599558B2 (en) 2026-04-14
PL2861214T3 (pl) 2021-02-08
RU2014148284A (ru) 2016-08-10
BR112014031278A2 (pt) 2017-06-27
EP3782606A1 (en) 2021-02-24
HUE051761T2 (hu) 2021-03-29

Similar Documents

Publication Publication Date Title
US12599558B2 (en) Tailored liposomes for the treatment of bacterial infections
US10632070B2 (en) Hydrogel toxin-absorbing or binding nanoparticles
CN107072944B (zh) 具有抗非结核分枝杆菌活性的脂质体环丙沙星制剂
Diab et al. Insights in nanoparticle-bacterium interactions: new frontiers to bypass bacterial resistance to antibiotics
JP2009536612A (ja) 脂質を用いた薬物製剤の高速送達とその処置方法
CN101511430A (zh) 抗生素组合物
US20200138710A1 (en) Compositions with permeation enhancers for drug delivery
JP2024023208A (ja) 肺炎の治療
HK40046902A (en) Tailored liposomes for the treatment of bacterial infections
RU2780026C2 (ru) Специально разработанные липосомы для лечения бактериальных инфекций
Selim et al. Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens
US20230293628A1 (en) Means and methods for treating bacterial infections
HK1210018B (zh) 用於治疗细菌感染的定制脂质体
US20210007985A1 (en) Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180419

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603